-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$51.50117.85% Upside
Dianthus Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Dianthus Therapeutics, Inc.?
Dianthus Therapeutics, Inc. has been rated by research analysts at Oppenheimer, Raymond James in the past 90 days.